Hosted on MSN15h
Growth brings higher profits at Germany's Merck
Driven by growth across the board, including in its semiconductor business, German science and technology company Merck ...
bnnbloomberg16h
Merck KGaA Beats Estimates on Boost From Life Science Unit
(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...
Hosted on MSN16h
Merck KGaA Expects Sales at Lower End of Outlook Range After Third-Quarter Miss
Germany’s Merck KGaA expects annual sales to be at the lower half of its outlook range after third-quarter sales missed ...
Reuters19h
Merck KGaA Q3 earnings rise faster than expected on lower costs
FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly ...
Mersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...
manilatimes1d
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
Collaborations: Mersana continues to advance its Johnson & Johnson and Merck KGaA, Darmstadt, Germany collaborations. The ...
Abbisko: Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial
The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p- Statistically significant ...
Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Phase III MANEUVER trial ...